#jolibetph

TORONTO, ON / ACCESSWIRE / December 4, 2024 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") announces that it has successfully settled a previously announced private placement of USD 175 million senior secured green bonds. The bonds will have a tenor of five years and a fixed coupon rate of 9.5% percent per annum, with interest payable in semi-annual instalments. Furthermore, the Green Bond will include a tap feature, allowing for access to an additional USD $50 million in funding for potential future uses. The bond issue is rated BB- by S&P Global Ratings and is issued under the Company's green finance framework with second-party opinion from Morningstar Sustainalytics. Marc Murnaghan, Chief Executive Officer of Polaris comments: "We are very pleased to successfully settle this inaugural bond issue with strong interest from a wide set of international investors. The bond optimizes the Company's capital structure and secures financing for further growth and increased diversification of cash flow." Net proceeds of the bonds will be used to refinance certain existing debt facilities, the acquisition of the Punta Lima wind farm in Puerto Rico and other investments in renewable energy assets. Pareto Securities acted as lead manager and sole bookrunner for the bond issue. National Bank Financial Inc. acted as Capital Markets Advisor on the transaction. The bonds have not been and will not be qualified for distribution in any province or territory of Canada. Accordingly, the bonds may not be offered or sold within any such province or territory except in transactions exempt from the prospectus requirements of applicable securities laws. No securities regulatory authority has either approved or disapproved the contents of this press release. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the bonds in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the development, construction, acquisition, and operation of renewable energy projects in five countries in Latin America and the Caribbean. The Company's operations include a geothermal plant (~82 MW), four run-of river hydroelectric plants (~40 MW), three solar (photovoltaic) projects in operation (~35 MW) and one wind park (26 MW) following closing of the Puerto Rico acquisition. For more information, contact: Investor Relations Polaris Renewable Energy Inc. Phone: +1 647-245-7199 Email: info@PolarisREI.com Cautionary Statements This press release contains certain "forward-looking information" which may include, but is not limited to, statements with respect to future events or future performance, the expected use of proceeds or rating(s) of any such issuance, the Company's acquisition and other investment plans, any benefits to the Company's financial or business performance, the settlement date of the bonds and the listing of the bonds on the Oslo Alternative Bond Market. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. Such factors include, among others, the ability of the Company to satisfy any interest payments, which may be affected by such factors as general business, economic, competitive, political and social uncertainties; the actual results of current geothermal, solar and hydro energy production, development and/or exploration activities and the accuracy of probability simulations prepared to predict prospective geothermal resources; changes in project parameters as plans continue to be refined; possible variations of production rates; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the geothermal and hydro power industries; political instability or insurrection or war; labour force availability and turnover; delays in obtaining governmental approvals or in the completion of development or construction activities, or in the commencement of operations; the ability of the Company to continue as a going concern and general economic conditions, as well as those factors discussed in the section entitled "Risk Factors" in the Company's Annual Information Form. These factors should be considered carefully and readers of this press release should not place undue reliance on forward-looking information. Although the forward-looking information contained in this press release is based upon what management believes to be reasonable assumptions, there can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The information in this press release, including such forward-looking information, is made as of the date of this press release and, other than as required by applicable securities laws, Polaris assumes no obligation to update or revise such information to reflect new events or circumstances. SOURCE: Polaris Renewable Energy Inc. View the original on accesswire.comPharrell Williams is hardly ever photographed without his red-strapped Richard Mille RM UP-01, which, at 1.75 mm, is the thinnest watch in the world. (At the time, it beat Bulgari’s Octo Finissimo record holder by 0.05 mm, but has since been eclipsed again by the Italian house.) A long-time friend of the brand, he even collaborated on the RM 52-05 . So, now that he has a new favorite Richard Mille in constant rotation, the musician, producer, and creative director is parting ways with his red-strapped RM 65-01 . The piece, open for bidding through December 13th on Williams’ ultra-hip auction platform Joopiter with a starting bid of a whopping $320,000, has serious provenance. Not only is it one-of-a-kind, but the caseback also sports the artist’s signature. Beyond these rare attributes, the timepiece is a highly complex piece of horology. Five years in the making, the RM 65-01 debuted in 2020 and is the most extraordinary piece, from a technological standpoint, the brand has ever created. With over 600 components, it comes equipped with a split-seconds chronograph (a notoriously difficult complication to craft) and a rapid automatic-winding system in the skeletonized caliber RMAC4 based on the Vaucher VMF 6710. Operating at 5 Hz or 36,000 vibrations per hour, it boasts exceptional precision. All of this is packaged in an intricate architecture while elements of the watch incorporate ultra-durable Carbon TPT—both hallmarks of the brand. Richard Mille collectors will notice the starting bid of the 18-karat rose gold piece is about the same as the original retail price of the original non-Pharrell-signed models. Still, it not only comes with Williams’ stamp, but it also comes with a unique experience. Richard Mille will invite the winning bidder to attend one of its ultra-VIP global events, which could mean anything from its Rallye des Légendes cross-Atlantic car rally to one of its annual yachting events such as the Richard Mille cup , its classic yachting race or its sponsorship of Les Voiles de St. Barth’s Regatta . The winner can bring a guest and choose which event best fits their schedule. Unfortunately, this RM 65-01 does not come with a meeting with Pharrell Williams himself, but it does come with plenty more bragging rights than recent versions of the timepiece to pop up on the market. Tom Brady will also auction his RM 65-01 on December 10th in “ The GOAT Collection” sale at Sothbey’s. His version, estimated at $250,000-$450,000, does not come with his signature. Another was sold at Christie’s “Rare Watches Including Watches for ELA” sale for CHF 403,200 (approximately $456,600) on November 11th, with proceeds going to benefit the European Leukodystrophy Association. Proceeds from the sale of Williams’ RM 65-01 will also be donated to charity. The proceeds will benefit Black Ambition—a non-profit founded by the entertainer to invest in start-ups created by black and Hispanic entrepreneurs. Happy bidding!#jolibetph 。

Judge rejects request to sideline SJSU volleyball player

The golf driver I just bought is over 50% off right now — grab a Cobra Aerojet for a steal

REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement Confirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatment Additional 4 patients demonstrated a best response of stable disease (SD) for up to 6 months of treatment Plans to continue monotherapy dose escalation and initiate combination studies in 1H 2025 SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. These results were presented today after market close at an AACR Special Conference in Cancer Research. The company will also hold a webinar on December 10 at 6:30 AM MT / 8:30 AM ET / 1:30 PM GMT to present the preliminary data broadcast from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts with an opportunity to submit questions here . "Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers," said David Hallett, Ph.D., Chief Scientific Officer of Recursion. "By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index. Using our precision design platform, we created a molecule with rapid oral absorption to reduce GI tissue exposure, a suitable half life to manage side effects, and target engagement covering the IC80 level." ELUCIDATE is an ongoing Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) of REC-617 in patients with advanced solid tumors. As of the November 15, 2024 data cutoff, preliminary findings include 18 patients with advanced solid tumors who were response evaluable in the monotherapy dose-escalation phase. Doses ranged from 2 mg to 20 mg once daily (QD) and 1 mg twice daily (BID). REC-617 was generally well-tolerated across all dose levels, with no discontinuations due to adverse events (AEs). Adverse events to date were predominately Grade 1-2, on-target, and reversible. An MTD has not yet been reached. While efficacy was not an endpoint in this Phase 1 study, or anticipated in monotherapy, a confirmed durable partial response (PR) by RECIST on REC-617 monotherapy was achieved in a patient with metastatic, platinum-resistant ovarian cancer. The response is on-going after more than 6 months of treatment. This patient had progressed following 4 lines of prior therapy in the advanced setting. In addition, four patients achieved a best response of stable disease (SD) across multiple dose levels for up to 6 months of treatment. "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer, Recursion. "Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." In parallel to the ongoing monotherapy dose escalation (QD and BID), combination studies are expected to initiate for ELUCIDATE in H1, 2025. The company expects to present additional ELUCIDATE as well as preclinical REC-617 data at future medical meetings. Summary of Interim REC-617 Monotherapy Dose Escalation Results Study Design & Demographics Phase 1 monotherapy dose escalation in advanced solid tumors Data cutoff as of November 15, 2024 - 19 patients enrolled (18 response evaluable) Heavily pre-treated population (median of 4 prior lines of therapy in the advanced setting) Antiemetics and anti-diarrheals not mandated prophylaxis for nausea/vomiting/diarrhea PK/PD Summary REC-617 exceeds CDK7 IC 80 with rapid absorption (Tmax 0.5–2 hours) with a half-life of 5-6 hours Early POLR2A 3-4x modulation suggests ~80–90% target engagement Quick, time-limited target engagement with POLR2A normalization in 24 hours Twice-daily (BID) dosing under investigation Safety Profile/AE Summary Adverse events (AEs) were predominantly low grade, on-target, and reversible upon treatment cessation Early data indicates a favorable safety profile – maximum tolerated dose (MTD) not reached No treatment discontinuations due to AEs 3 treatment related serious adverse events (SAE)s reported in 2/19 patients Events resolved and treatment continued after dose reduction Antiemetics and anti-diarrheals not mandated prophylaxis for nausea/vomiting/diarrhea Confirmed Partial Response & Stable Disease Summary One confirmed partial response (PR) by RECIST 1.1 (decrease of more than 30% in the sum of the longest diameters of target lesions + no new lesions + no progression of non target lesions) Partial response (-34%) achieved with reduction of 2 lymph nodes (para-aortic and mesenteric) at Week 16 with normalization of LDH Reduction of tumor marker CA125 from 1249 to 694 kU/L (-44%) Reduction of tumor marker TK1 from 174 to 56 DuA (-68%) Response ongoing after more than 6 months of treatment Patient continues study therapy without need for antiemetics Four additional patients achieved durable (up to 6 months of treatment) response of stable disease (SD) as best response across multiple dose levels All four patients progressed prior to entering the study Three CRC patients (6L-7L) and one NSCLC patient (4L) One patient on 2mg QD and three patients on 10mg QD About REC-617 REC-617 is a potential best-in-class CDK7 inhibitor, precision designed using AI-led approaches, with only 136 novel molecule synthesized from hit to candidate identification in less than 12 months. The molecule is designed to maximize its therapeutic index by enabling the tight control of both the extent and duration of target inhibition. CDK7 inhibition combines many potential benefits such as transcription inhibition, reduction of aberrant kinome activation, cell cycle inhibition, and modulation of estrogen receptor activity. This makes it an attractive target to overcome common resistance pathways associated with CDK4/6 inhibition, which only targets the cell cycle. About ELUCIDATE REC-617 is currently being evaluated as a monotherapy in the ELUCIDATE trial. ELUCIDATE is a multicenter, open-label, two-stage clinical trial to evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy of REC-617 in advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, head and neck cancer. Both the monotherapy and combination therapy dose escalation portion of the trial will enroll patients across multiple dose levels to determine the optimal biological dose (OBD). The dose expansion phase of the trial will commence upon identification of the OBD. The primary efficacy endpoint of the expansion phase is objective response rate (ORR). About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at www.Recursion.com , or connect on X (formerly Twitter) and LinkedIn. Media Contact Media@Recursion.com Investor Contact Investor@Recursion.com Forward-Looking Statements This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the potential efficacy of REC-617; timing of the Phase 1/2 clinical trial of REC-617; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.President-elect Donald Trump has chosen Republican U.S. Rep. Lori Chavez-DeRemer as his nominee to l e ad the Labor Department . The Oregon House member who narrowly lost her reelection bid earlier this month received strong backing from union members in her district. Philadelphia news 24/7: Watch NBC10 free wherever you are As a potential labor secretary, Chavez-DeRemer would oversee the Labor Department’s workforce and its budget and put forth priorities that impact workers’ wages, health, safety and ability to unionize, and employers' rights to fire employees, among other responsibilities. “Lori’s strong support from both the Business and Labor communities will ensure that the Labor Department can unite Americans of all backgrounds behind our Agenda for unprecedented National Success - Making America Richer, Wealthier, Stronger and more Prosperous than ever before!” Trump said in a statement. This is a developing story. Please check back for updates. Trump appointments and nominees Here are some of the people that President-elect Donald Trump has named for high-profile positions in his administration. Positions in orange require Senate confirmation. Source: NBC News

Unai Emery feels confidence returning after Aston Villa end winless run

Chance of direct attack by Russia ‘remote’, says UK armed forces chiefA proposal to ban a transgender Montana lawmaker from using the women’s bathroom in the state's capitol building failed on Tuesday. The proposed amendment, introduced by Republican Rep. Jerry Schillinger of Circle, would have required state legislators to use restrooms based on their biological sex at birth. The amendment needed to receive a majority from House members and Senate members on the joint rules committee to advance. It got enough votes to pass on the Senate side, but not the House. Rep. Zooey Zephyr, D-Missoula, was Montana’s first openly transgender female lawmaker. Rep. SJ Howell, D-Missoula, was the first nonbinary lawmaker. Both were first elected in 2022 and reelected this year. RELATED STORY | Montana transgender lawmaker on Capitol Hill's bathroom ban: 'Do not cede ground' On social media, Zephyr thanked her colleagues — particularly her republican colleagues — who she said “recognized this as a distraction from the work we were elected to do.” Rep. David Bedey, R-Hamilton, one of four Republicans to vote against the proposal, said, “This particular action will have the effect of making people famous in the national news and will not contribute to the effective conduct of our business." This comes after some intense moments last month in Washington after a Republican representative from South Carolina proposed a similar ban on Capitol Hill ahead of the first openly transgender member of Congress, Rep. Sarah McBride, D-Delaware, taking office next year. RELATED STORY | Justices seemingly unmoved to overturn transgender health care ban for minors

The Philadelphia Phillies signed two-time All-Star closer Jordan Romano to a one-year contract on Monday. Financial terms were not disclosed, but ESPN and The Athletic reported the deal was worth $7.75 million. The 31-year-old right-hander was non-tendered by Toronto earlier this offseason. The Phillies bolstered their bullpen after Jeff Hoffman and Carlos Estevez hit free agency. Romano went 1-2 with a 6.59 ERA in 15 relief appearances with the Blue Jays in 2024. Romano battled injuries last season and underwent season-ending right elbow surgery in July. He saved 36 games in 2022 and 2023, earning All-Star nods in each season. Overall, Romano is 20-17 in 231 career relief appearances with 105 saves and a 2.90 ERA. --Field Level Media

Kirk Herbstreit shares heartfelt letter from Joe Biden after death of beloved dog Ben

Police probe launched after tractor driver sent waves of Storm Bert floodwaters smashing through shop windows while speeding through Worcestershire townLook Ahead: Local events and things to do this week, Dec. 29-Jan. 4None